Deal News

PCM Trials acquires EmVenio to boost decentralised clinical trials

PCM Trials has acquired US-based EmVenio Research, a community-based clinical trial site provider equipped with mobile research units, to design…

Signal: Tweets of the week focus on Eli Lilly’s most recent acquisitions

Eli Lilly continues to make news by announcing its complete acquisition of the Massachusetts-headquartered Sigilon on 14 August. The deal…

BioVaxys Technology buys clinical studies management company TAETSoftware

BioVaxys Technology has acquired clinical studies management company TAETSoftware (TAETCo), which develops and commercialises the Trial Adverse Events Tracker (TAET)…

IGM and ADC enter clinical trial partnership deal for lymphoma treatment

IGM Biosciences has signed a clinical trial partnership and supply agreement with ADC Therapeutics to analyse the combination of imvotamab and…

Erasca and Pfizer enter trial partnership for palbociclib

Erasca and Pfizer have entered a clinical trial partnership and supply agreement for palbociclib (Ibrance), an inhibitor of CDK4/6. Under the collaboration, the companies…

GSK and Tempus partner to boost clinical trial design

GSK has signed a three-year partnership agreement with Tempus to enhance clinical trial design, expedite subject enrolment and detect drug targets. Under the…

Lightship and Acclinate to boost trial access for underrepresented people

Lightship has entered a collaboration with Acclinate to boost access and engagement in clinical trials for populations which are underrepresented.…

TILT Biotherapeutics and MSD partner for lung cancer treatment trial

TILT Biotherapeutics and MSD (Merck) have entered a clinical trial collaboration and supply agreement for an oncolytic immunotherapy candidate, TILT-123, for non-small cell lung…

Pfizer and Strata expand clinical partnership for cancer trial

Pfizer and Strata Oncology have expanded their partnership for a clinical trial assessing various cancer therapies in new, biomarker-guided patient groups. Named Strata…

OncoResponse and Regeneron enter cancer therapy clinical supply agreement

OncoResponse has entered a clinical supply agreement with Regeneron for the latter’s Libtayo (cemiplimab), a PD-1 inhibitor. The deal will…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close